Kunal Nepali

Dr. Kunal Nepali


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KNKunal Nepali
Kunal Nepali
Sahil SharmaSahil Sharma
Sahil Sharma
MSManmohan Sharma
Manmohan Sharma
PBPreet Mohinder Singh Bedi
Preet Mohinder Singh Bedi
KDK.L. Dhar
K.L. Dhar

5 July 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
ATAmandeep Thakur
Amandeep Thakur
CFChetna Faujdar
Chetna Faujdar
RSRam Sharma
Ram Sharma
SSSachin Sharma
Sachin Sharma
BMBasant Malik
Basant Malik
JLJing-Ping Liou
Jing-Ping Liou
Glioblastoma (GBM) is a highly malignant brain tumor characterized by a heterogeneous population of genetically unstable and highly infiltrative cells that are resistant to chemotherapy. Although substantial efforts have been invested in the field of anti-GBM drug discovery in the past decade, success has primarily been confined to the preclinical level, and clinical studies have often been hampered due to efficacy-, selectivity-, or physicochemical property-related issues. Thus, expansion of the list of molecular targets coupled with a pragmatic design of new small-molecule inhibitors with central nervous system (CNS)-penetrating ability is required to steer the wheels of anti-GBM drug discovery endeavors. This Perspective presents various aspects of drug discovery (challenges in GBM drug discovery and delivery, therapeutic targets, and agents under clinical investigation). The comprehensively covered sections include the recent medicinal chemistry campaigns embarked upon to validate the potential of numerous enzymes/proteins/receptors as therapeutic targets in GBM.

16 December 2014 in Recent Patents on Anti-Cancer Drug Discovery
Verified
Journal Article
Closed access
PDF file
RKRamandeep Kaur
Ramandeep Kaur
PKPrabhkirat Kaur
Prabhkirat Kaur
Sahil SharmaSahil Sharma
Sahil Sharma
GSGurpreet Singh
Gurpreet Singh
SMSamir Mehndiratta
Samir Mehndiratta
KNKunal Nepali
Kunal Nepali
Pyrimidine ring is the building unit of DNA and RNA and thus pyrimidine based chemical architectures exhibit diverse pharmacological activities. Among the reported medicinal attributes of pyrimidines, anticancer activity is the most extensively reported. The anticancer potential of pyrimidines in fused scaffolds has also been evidenced through number of research article and patent literature. The pyrimidines based scaffolds have exerted their cell killing effects through varied mechanisms which indicate their potential to interact with diverse enzymes/ targets/receptors. This review article strictly focuses on the patent literature from 2009 onwards. The structure of the potent compounds, their IC50 values, models/assays used for the anticancer evaluation and the enzymes/ receptors/ targets involved have been presented in this compilation. Significant number of patents i.e. 59 have been published on pyrimidine based anticancer agents from 2009-2014 (from 2009 through the present date) which clearly indicate that this heterocycle is an area of focus at present for researchers all over the globe. Moreover, out of the 59 patents published during this period, 32 have been published from 2012 onwards which further highlights the present interest of the researcher towards pyrimidine based anticancer agents. The promising activity displayed by these pyrimidine based scaffolds clearly places them in forefront as potential future drug candidates. The present compilation can be extremely beneficial for the medicinal chemists working on design and synthesis of anticancer drugs.

28 November 2016 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
RORitu Ojha
Ritu Ojha
JSJagjeet Singh
Jagjeet Singh
AOAnu Ojha
Anu Ojha
HSHarbinder Singh
Harbinder Singh
Sahil SharmaSahil Sharma
Sahil Sharma
KNKunal Nepali
Kunal Nepali
Introduction: Xanthine oxidase (XO) is a versatile molybdoflavoprotein, widely distributed, occurring in milk, kidney, lung, heart, and vascular endothelium. Catalysis by XO to produce uric acid and reactive oxygen species leads to many diseases. Anti hyperuricemic therapy by xanthine oxidase inhibitors has been mainly employed for the treatment of gout. Area covered: This review covers the patent literature (2011–2015) and also presents the interesting strategies/rational approaches employed for the design of xanthine oxidase inhibitors reported recently. Expert opinion: Recent literature indicates that various non purine scaffolds have been extensively investigated for xanthine oxidase inhibition. The significant potential endowed by heteroaryl based compounds, in particularly fused heterocycles clearly highlights their clinical promise and the need for detailed investigation. Studies by various research groups have also revealed that the flavone framework is open for isosteric replacements and structural modifications for yielding potent non purine xanthine oxidase inhibitors. In addition, various plant extracts recently reported to possess significant xanthine oxidase inhibitory potential presents enough promise to initiate a screening program for the identification of other plant extracts and phytoconstituents possessing inhibitory potential towards the enzyme.

18 October 2012 in Archiv der Pharmazie
Verified
Journal Article
Closed access
PDF file
RDRajni Dhiman
Rajni Dhiman
Sahil SharmaSahil Sharma
Sahil Sharma
GSGagandip Singh
Gagandip Singh
KNKunal Nepali
Kunal Nepali
PBPreet Mohinder Singh Bedi
Preet Mohinder Singh Bedi

2 June 2015 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
RKRamandeep Kaur
Ramandeep Kaur
FNFatima Naaz
Fatima Naaz
Sahil SharmaSahil Sharma
Sahil Sharma
SMSamir Mehndiratta
Samir Mehndiratta
MGManish Kumar Gupta
Manish Kumar Gupta
KNKunal Nepali
Kunal Nepali